Press Release | Amplyx - Part 2

Amplyx Pharmaceuticals Demonstrates APX001 has Potent Activity Against Deadly Multidrug-Resistant Candida Species

04/30/2018/by jnellis

Amplyx Pharmaceuticals Receives Fourth “Qualified Infectious Disease Product” (QIDP) Designation from the FDA for APX001

03/19/2018/by admin

Amplyx Pharmaceuticals Announces Appointment of CFO and Presentation at the J.P. Morgan 36th Annual Healthcare Conference

01/08/2018/by admin

Amplyx Pharmaceuticals Highlights Phase 1 APX001 Data at IDWeek 2017

10/09/2017/by admin

Amplyx Pharmaceuticals Announces Presentations at IDWeek 2017

09/21/2017/by admin

Amplyx Pharmaceuticals Raises $67 Million in Series C Financing

08/01/2017/by admin

Amplyx Pharmaceuticals Appoints Ciara Kennedy, Ph.D., as President and Chief Executive Officer

01/05/2017/by admin

FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Multiple Invasive Fungal and Mold Infections

11/15/2016/by admin

Amplyx Pharmaceuticals Initiates Dosing in Phase 1 Clinical Trial of APX001, a Novel Antifungal Product Candidate for Treatment of Life-Threatening Infections

09/12/2016/by admin

Amplyx Pharmaceuticals Appoints Paul C. Grint, M.D., to Board of Directors

05/24/2016/by admin